Evidence map›Paper›PMID 31671663›Full record

ArticleInternational journal of molecular sciences2019

Gender Differences in the Pharmacological Actions of Pegylated Glucagon-Like Peptide-1 on Endothelial Progenitor Cells and Angiogenic Precursor Cells in a Combination of Metabolic Disorders and Lung Emphysema.

Olga Victorovna Pershina, Angelina Vladimirovna Pakhomova, Darius Widera, Natalia Nicolaevna Ermakova, Anton Alexandrovich Epanchintsev, Edgar Sergeevich Pan, Vyacheslav Andreevich Krupin, Olga Evgenevna Vaizova, Olesia Dmitrievna Putrova, Lubov Alexandrovna Sandrikina and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Endothelial progenitor cells and chronic obstructive pulmonary disease: From basic research to clinical application.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  4. Advances in metabolomics of chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2023
    Review
  5. Article
  6. Peptides for Health Benefits 2019.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Olga Victorovna PershinaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. ovpershina@gmail.com.
Angelina Vladimirovna PakhomovaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. angelinapakhomova2011@gmail.com.
Darius WideraStem Cell Biology and Regenerative Medicine Group, School of Pharmacy, University of Reading, Whiteknights campus, Reading, RG6 6AP, UK. d.widera@reading.ac.uk.
Natalia Nicolaevna ErmakovaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. nejela@mail.ru.
Anton Alexandrovich EpanchintsevBranch Federal State Unitary Enterprise "Scientific and Production Association for Immunological Preparations "Microgen" of Ministry of Health of the Russian Federation "SIC "Virion", 634040 Tomsk, Russia. a.a.epanchintsev@gmail.com.
Edgar Sergeevich PanLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. artifexpan@gmail.com.
Vyacheslav Andreevich KrupinLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. vakrupin88@gmail.com.
Olga Evgenevna VaizovaDepartment of Pharmacology, Siberian State Medical University, 634050 Tomsk, Russia. vaizova@mail.ru.
Olesia Dmitrievna PutrovaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. olesya.putrova@mail.ru.
Lubov Alexandrovna SandrikinaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. ermolaeva_la@mail.ru.
Irina Vitalevna KurochkinaLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. irinakuro4kina93@yandex.ru.
Sergey Georgievich MorozovInstitute of General Pathology and Pathophysiology, 125315 Moscow, Russia. biopharm@list.ru.
Aslan Amirkhanovich KubatievInstitute of General Pathology and Pathophysiology, 125315 Moscow, Russia. niiopp@mail.ru.
Alexander Mikhaylovich DygaiLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. amdygay@gmail.com.
Evgenii Germanovich SkurikhinLaboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, 634028 Tomsk, Russia. eskurihin@inbox.ru.
Russian Academy of Sciences · RUResearch Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RUNational Research Tomsk State University · RUSiberian State Medical University · RUUniversity of Reading · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical practice, the metabolic syndrome (MetS) is often associated with chronic obstructive pulmonary disease (COPD). Although gender differences in MetS are well documented, little is known about sex-specific differences in the pathogenesis of COPD, especially when combined with MetS. Consequently, it is not clear whether the same treatment regime has comparable efficacy in men and women diagnosed with MetS and COPD. In the present study

Indexed as

AnimalsCigarette SmokingDisease Models, AnimalEndothelial Progenitor CellsFemaleGlucagon-Like Peptide 1HumansLipopolysaccharidesMaleMetabolic SyndromeMice, Inbred C57BLPulmonary Disease, Chronic ObstructivePulmonary EmphysemaSex CharacteristicsSodium GlutamateTreatment OutcomeGlucagon-Like Peptide 1LipopolysaccharidesSodium Glutamateand endothelial regenerationangiogenic precursor cellsdyslipidemiaendothelial progenitor cellsgender differenceshyperglycemiaobesitypegylated glucagon-like peptide 1pulmonary emphysema

Identifiers

PMID31671663
PMCPMC6862381
OpenAlexW2982363792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.